Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of an 18F-labeled anti-human CD8 VHH for same-day immunoPET imaging.
Sriraman SK, Davies CW, Gill H, Kiefer JR, Yin J, Ogasawara A, Urrutia A, Javinal V, Lin Z, Seshasayee D, Abraham R, Haas P, Koth C, Marik J, Koerber JT, Williams SP. Sriraman SK, et al. Eur J Nucl Med Mol Imaging. 2023 Feb;50(3):679-691. doi: 10.1007/s00259-022-05998-0. Epub 2022 Nov 8. Eur J Nucl Med Mol Imaging. 2023. PMID: 36346438
Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Ogasawara A, et al. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):287-301. doi: 10.1007/s00259-022-05968-6. Epub 2022 Oct 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 36271158
Correction to: Preclinical development of ZED8, an 89Zr immuno‑PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy.
Ogasawara A, Kiefer JR, Gill H, Chiang E, Sriraman S, Ferl GZ, Ziai J, Bohorquez SS, Guelman S, Wang X, Yang J, Phan MM, Nguyen V, Chung S, Yu C, Tinianow J, Waaijer SJH, De Crespigny A, Marik J, Boswell CA, Zabka T, Staflin K, Williams SP. Ogasawara A, et al. Eur J Nucl Med Mol Imaging. 2023 Jan;50(2):631. doi: 10.1007/s00259-022-06050-x. Eur J Nucl Med Mol Imaging. 2023. PMID: 36427067 No abstract available.
Ceramide limits phosphatidylinositol-3-kinase C2β-controlled cell motility in ovarian cancer: potential of ceramide as a metastasis-suppressor lipid.
Kitatani K, Usui T, Sriraman SK, Toyoshima M, Ishibashi M, Shigeta S, Nagase S, Sakamoto M, Ogiso H, Okazaki T, Hannun YA, Torchilin VP, Yaegashi N. Kitatani K, et al. Among authors: sriraman sk. Oncogene. 2016 May;35(21):2801-12. doi: 10.1038/onc.2015.330. Epub 2015 Sep 14. Oncogene. 2016. PMID: 26364609 Free PMC article.
Barriers to drug delivery in solid tumors.
Sriraman SK, Aryasomayajula B, Torchilin VP. Sriraman SK, et al. Tissue Barriers. 2014 Jul 22;2:e29528. doi: 10.4161/tisb.29528. eCollection 2014. Tissue Barriers. 2014. PMID: 25068098 Free PMC article. Review.